An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

NCT ID: NCT06315283

Last Updated: 2025-11-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 153 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-20
• Study Completion Date: 2025-09-04

Brief Summary

The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia.

A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia.

Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia.

The total duration of participation in the trial for each participant is planned to be approximately 21 weeks.

Conditions

Schizophrenia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Oral olanzapine

Group Type: ACTIVE_COMPARATOR

Oral olanzapine

Intervention Type: DRUG

Administered orally

TV-44749

Group Type: EXPERIMENTAL

TV-44749

Intervention Type: DRUG

Administered subcutaneously (sc)

Interventions

TV-44749

Administered subcutaneously (sc)

Intervention Type: DRUG

Oral olanzapine

Administered orally

Intervention Type: DRUG

Other Intervention Names

Olanzapine; ZYPREXA®

Eligibility Criteria

Inclusion Criteria

• Agree to maintain current smoking or nonsmoking status at the time informed consent is obtained and throughout the trial until completion of the EOT or ET visit (ie, nonsmoking participants must agree not to start smoking and participants who smoke will be excluded if they plan to discontinue smoking during the trial period).
• Have a current confirmed diagnosis of schizophrenia according to an evaluation by the Investigator, as defined by the DSM-5 (American Psychiatric Association 2013a).
• Are clinically stable on oral olanzapine 20 mg daily (ie, dose has not changed in the last 4 weeks) and not currently on other antipsychotic treatments at the time of screening. Participants on alternative olanzapine regimens (eg, 10 mg twice daily) may be considered for inclusion in the trial based upon the Investigator's clinical judgment.
• Women may be included only if they have a negative serum beta human chorionic gonadotropin (HCG) test result at screening; they are surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal (postmenopausal status will be confirmed by a follicle-stimulating hormone screen according to the clinical laboratory standard value) for at least 1 year; or they are practicing a highly effective method of birth control and not planning pregnancy for at least 30 days before the trial, for the duration of the trial, and for 70 days after the last dose administration, if they are sexually active and of childbearing potential.
• Men must be sterile; or if they are potentially of reproductive competence and have sexual relationship with female partners of childbearing potential, they must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 70 days after the last dose administration.

NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion Criteria

• History or known risk of narrow-angle glaucoma.
• History or a complication of diabetes (hemoglobin A1c 6.5% or above and/or fasting plasma glucose 126 mg/dL or above).
• Evidence of significant hepatic disorder.
• The participant is a pregnant or lactating woman or plans to become pregnant during the trial or within 70 days after the last dose administration.
• Known hypersensitivity or idiosyncratic reaction to olanzapine (or unable to tolerate oral olanzapine dose) or any of the excipients of TV-44749 in any formulation, their related compounds, or to any metabolites, or any compound listed as being present in TV-44749 or oral olanzapine.
• Presence of excessive pigment, bruises, scars, or tattoos around the potential injection area.
• Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, long QT syndrome, personal history of syncope, or history of uncontrolled high blood pressure. Participants with history of high blood pressure who no longer require treatment or participants who are treated with antihypertensive medications and whose blood pressure is currently well-controlled, may be enrolled.
• Substance use disorder criteria for alcohol, drug, or any other substance dependence (with the exception of nicotine or caffeine) have been met within the past 12 months prior to screening as defined by the DSM-5 (American Psychiatric Association 2013b).
• A current clinically significant DSM-5 diagnosis other than schizophrenia.

NOTE- Additional criteria apply, please contact the investigator for more information

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Teva Branded Pharmaceutical Products R&D LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Teva Medical Expert, MD

Role: STUDY_DIRECTOR

Teva Branded Pharmaceutical Products R&D LLC

Locations

Teva Investigational Site 15739

Los Alamitos, California, United States

Teva Investigational Site 15740

Torrance, California, United States

Teva Investigational Site 15738

Hollywood, Florida, United States

Teva Investigational Site 15741

Atlanta, Georgia, United States

Teva Investigational Site 15742

Decatur, Georgia, United States

Teva Investigational Site 15737

Marlton, New Jersey, United States

Teva Investigational Site 60053

Zagreb, , Croatia

Teva Investigational Site 31326

Zamora, , Spain

Teva Investigational Site 34310

Surrey, , United Kingdom

Countries

United States; Croatia; Spain; United Kingdom

Other Identifiers

2023-505664-11-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

TV44749-BA-10196

Identifier Type: -

Identifier Source: org_study_id